Financhill
Sell
34

PLX Quote, Financials, Valuation and Earnings

Last price:
$1.61
Seasonality move :
10.54%
Day range:
$1.56 - $1.66
52-week range:
$0.82 - $3.10
Dividend yield:
0%
P/E ratio:
39.00x
P/S ratio:
2.19x
P/B ratio:
2.75x
Volume:
1.4M
Avg. volume:
1.2M
1-year change:
26.83%
Market cap:
$124.2M
Revenue:
$53.4M
EPS (TTM):
$0.04

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PLX
Protalix BioTherapeutics
$21.6M -- -14.21% -- $14.00
ARMP
Armata Pharmaceuticals
$1.4M -$0.38 -- -56% $9.00
CATX
Perspective Therapeutics
$143.9K -$0.27 -- -55.87% $13.8214
INO
Inovio Pharmaceuticals
$10K -$0.74 -91.73% -48.57% $7.50
NXGL
NexGel
$2.7M -$0.10 113.89% -50% $6.00
SGMO
Sangamo Therapeutics
$7.4M -$0.13 8298.88% -44.44% $4.10
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PLX
Protalix BioTherapeutics
$1.56 $14.00 $124.2M 39.00x $0.00 0% 2.19x
ARMP
Armata Pharmaceuticals
$2.00 $9.00 $72.4M -- $0.00 0% 826.47x
CATX
Perspective Therapeutics
$2.4000 $13.8214 $178.1M -- $0.00 0% 16.92x
INO
Inovio Pharmaceuticals
$2.00 $7.50 $73.3M -- $0.00 0% --
NXGL
NexGel
$2.18 $6.00 $16.7M -- $0.00 0% 1.48x
SGMO
Sangamo Therapeutics
$0.45 $4.10 $111.2M -- $0.00 0% 1.51x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PLX
Protalix BioTherapeutics
-- 1.057 -- 1.62x
ARMP
Armata Pharmaceuticals
-- 2.116 -- --
CATX
Perspective Therapeutics
-- -1.032 -- --
INO
Inovio Pharmaceuticals
-- 0.725 -- 2.55x
NXGL
NexGel
11.28% -0.457 2.86% 0.84x
SGMO
Sangamo Therapeutics
-- 3.573 -- 0.60x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PLX
Protalix BioTherapeutics
$1.9M -$4.1M 8.88% 10.9% -36.84% -$5.4M
ARMP
Armata Pharmaceuticals
-- -$8.2M -- -- -- -$7.7M
CATX
Perspective Therapeutics
-- -$21.8M -- -- -- -$26.2M
INO
Inovio Pharmaceuticals
-- -$25.1M -125.47% -125.47% -30140.49% -$26.9M
NXGL
NexGel
$1.2M -$777K -51.9% -59.55% -23.41% -$400K
SGMO
Sangamo Therapeutics
-- -$29.6M -269.87% -269.87% -460.28% -$26.1M

Protalix BioTherapeutics vs. Competitors

  • Which has Higher Returns PLX or ARMP?

    Armata Pharmaceuticals has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of --. Protalix BioTherapeutics's return on equity of 10.9% beat Armata Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PLX
    Protalix BioTherapeutics
    19.11% -$0.05 $45.2M
    ARMP
    Armata Pharmaceuticals
    -- -$0.20 --
  • What do Analysts Say About PLX or ARMP?

    Protalix BioTherapeutics has a consensus price target of $14.00, signalling upside risk potential of 797.44%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $9.00 which suggests that it could grow by 350%. Given that Protalix BioTherapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Armata Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PLX
    Protalix BioTherapeutics
    0 0 0
    ARMP
    Armata Pharmaceuticals
    0 0 0
  • Is PLX or ARMP More Risky?

    Protalix BioTherapeutics has a beta of -0.048, which suggesting that the stock is 104.824% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.907, suggesting its less volatile than the S&P 500 by 9.252%.

  • Which is a Better Dividend Stock PLX or ARMP?

    Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PLX or ARMP?

    Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Protalix BioTherapeutics's net income of -$3.6M is higher than Armata Pharmaceuticals's net income of -$6.5M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 39.00x while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.19x versus 826.47x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PLX
    Protalix BioTherapeutics
    2.19x 39.00x $10.1M -$3.6M
    ARMP
    Armata Pharmaceuticals
    826.47x -- -- -$6.5M
  • Which has Higher Returns PLX or CATX?

    Perspective Therapeutics has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of --. Protalix BioTherapeutics's return on equity of 10.9% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PLX
    Protalix BioTherapeutics
    19.11% -$0.05 $45.2M
    CATX
    Perspective Therapeutics
    -- -$0.25 --
  • What do Analysts Say About PLX or CATX?

    Protalix BioTherapeutics has a consensus price target of $14.00, signalling upside risk potential of 797.44%. On the other hand Perspective Therapeutics has an analysts' consensus of $13.8214 which suggests that it could grow by 475.89%. Given that Protalix BioTherapeutics has higher upside potential than Perspective Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Perspective Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PLX
    Protalix BioTherapeutics
    0 0 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is PLX or CATX More Risky?

    Protalix BioTherapeutics has a beta of -0.048, which suggesting that the stock is 104.824% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

  • Which is a Better Dividend Stock PLX or CATX?

    Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PLX or CATX?

    Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than Perspective Therapeutics quarterly revenues of --. Protalix BioTherapeutics's net income of -$3.6M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 39.00x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.19x versus 16.92x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PLX
    Protalix BioTherapeutics
    2.19x 39.00x $10.1M -$3.6M
    CATX
    Perspective Therapeutics
    16.92x -- -- -$18.2M
  • Which has Higher Returns PLX or INO?

    Inovio Pharmaceuticals has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of -30140.49%. Protalix BioTherapeutics's return on equity of 10.9% beat Inovio Pharmaceuticals's return on equity of -125.47%.

    Company Gross Margin Earnings Per Share Invested Capital
    PLX
    Protalix BioTherapeutics
    19.11% -$0.05 $45.2M
    INO
    Inovio Pharmaceuticals
    -- -$0.51 $51.3M
  • What do Analysts Say About PLX or INO?

    Protalix BioTherapeutics has a consensus price target of $14.00, signalling upside risk potential of 797.44%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.50 which suggests that it could grow by 275%. Given that Protalix BioTherapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Inovio Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PLX
    Protalix BioTherapeutics
    0 0 0
    INO
    Inovio Pharmaceuticals
    2 3 0
  • Is PLX or INO More Risky?

    Protalix BioTherapeutics has a beta of -0.048, which suggesting that the stock is 104.824% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.401, suggesting its more volatile than the S&P 500 by 40.133%.

  • Which is a Better Dividend Stock PLX or INO?

    Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PLX or INO?

    Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than Inovio Pharmaceuticals quarterly revenues of $65.3K. Protalix BioTherapeutics's net income of -$3.6M is higher than Inovio Pharmaceuticals's net income of -$19.7M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 39.00x while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.19x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PLX
    Protalix BioTherapeutics
    2.19x 39.00x $10.1M -$3.6M
    INO
    Inovio Pharmaceuticals
    -- -- $65.3K -$19.7M
  • Which has Higher Returns PLX or NXGL?

    NexGel has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of -25.37%. Protalix BioTherapeutics's return on equity of 10.9% beat NexGel's return on equity of -59.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    PLX
    Protalix BioTherapeutics
    19.11% -$0.05 $45.2M
    NXGL
    NexGel
    42.34% -$0.09 $6.2M
  • What do Analysts Say About PLX or NXGL?

    Protalix BioTherapeutics has a consensus price target of $14.00, signalling upside risk potential of 797.44%. On the other hand NexGel has an analysts' consensus of $6.00 which suggests that it could grow by 175.23%. Given that Protalix BioTherapeutics has higher upside potential than NexGel, analysts believe Protalix BioTherapeutics is more attractive than NexGel.

    Company Buy Ratings Hold Ratings Sell Ratings
    PLX
    Protalix BioTherapeutics
    0 0 0
    NXGL
    NexGel
    0 0 0
  • Is PLX or NXGL More Risky?

    Protalix BioTherapeutics has a beta of -0.048, which suggesting that the stock is 104.824% less volatile than S&P 500. In comparison NexGel has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock PLX or NXGL?

    Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. NexGel pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PLX or NXGL?

    Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than NexGel quarterly revenues of $2.8M. Protalix BioTherapeutics's net income of -$3.6M is lower than NexGel's net income of -$712K. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 39.00x while NexGel's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.19x versus 1.48x for NexGel. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PLX
    Protalix BioTherapeutics
    2.19x 39.00x $10.1M -$3.6M
    NXGL
    NexGel
    1.48x -- $2.8M -$712K
  • Which has Higher Returns PLX or SGMO?

    Sangamo Therapeutics has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of -475.33%. Protalix BioTherapeutics's return on equity of 10.9% beat Sangamo Therapeutics's return on equity of -269.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    PLX
    Protalix BioTherapeutics
    19.11% -$0.05 $45.2M
    SGMO
    Sangamo Therapeutics
    -- -$0.14 $4.9M
  • What do Analysts Say About PLX or SGMO?

    Protalix BioTherapeutics has a consensus price target of $14.00, signalling upside risk potential of 797.44%. On the other hand Sangamo Therapeutics has an analysts' consensus of $4.10 which suggests that it could grow by 804.88%. Given that Sangamo Therapeutics has higher upside potential than Protalix BioTherapeutics, analysts believe Sangamo Therapeutics is more attractive than Protalix BioTherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PLX
    Protalix BioTherapeutics
    0 0 0
    SGMO
    Sangamo Therapeutics
    3 2 0
  • Is PLX or SGMO More Risky?

    Protalix BioTherapeutics has a beta of -0.048, which suggesting that the stock is 104.824% less volatile than S&P 500. In comparison Sangamo Therapeutics has a beta of 1.456, suggesting its more volatile than the S&P 500 by 45.634%.

  • Which is a Better Dividend Stock PLX or SGMO?

    Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Sangamo Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PLX or SGMO?

    Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than Sangamo Therapeutics quarterly revenues of $6.4M. Protalix BioTherapeutics's net income of -$3.6M is higher than Sangamo Therapeutics's net income of -$30.6M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 39.00x while Sangamo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.19x versus 1.51x for Sangamo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PLX
    Protalix BioTherapeutics
    2.19x 39.00x $10.1M -$3.6M
    SGMO
    Sangamo Therapeutics
    1.51x -- $6.4M -$30.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Tesla Stock Overvalued or a Buy for the Next Decade?
Is Tesla Stock Overvalued or a Buy for the Next Decade?

Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…

Is Apple Stock Undervalued or Overvalued?
Is Apple Stock Undervalued or Overvalued?

For many years, Apple (NASDAQ:AAPL) was just about the perfect…

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
58
TNXP alert for May 28

Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.

Sell
37
ATS alert for May 28

ATS [ATS] is down 1.27% over the past day.

Buy
88
SMR alert for May 28

NuScale Power [SMR] is down 0.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock